136 related articles for article (PubMed ID: 30187817)
1. Identification of a novel GORASP2-ALK fusion in an ALK-positive large B-cell lymphoma.
Ise M; Kageyama H; Araki A; Itami M
Leuk Lymphoma; 2019 Feb; 60(2):493-497. PubMed ID: 30187817
[No Abstract] [Full Text] [Related]
2. Detection of known and novel ALK fusion transcripts in lung cancer patients using next-generation sequencing approaches.
Vendrell JA; Taviaux S; Béganton B; Godreuil S; Audran P; Grand D; Clermont E; Serre I; Szablewski V; Coopman P; Mazières J; Costes V; Pujol JL; Brousset P; Rouquette I; Solassol J
Sci Rep; 2017 Oct; 7(1):12510. PubMed ID: 28970558
[TBL] [Abstract][Full Text] [Related]
3. Identification of a novel fusion, SQSTM1-ALK, in ALK-positive large B-cell lymphoma.
Takeuchi K; Soda M; Togashi Y; Ota Y; Sekiguchi Y; Hatano S; Asaka R; Noguchi M; Mano H
Haematologica; 2011 Mar; 96(3):464-7. PubMed ID: 21134980
[TBL] [Abstract][Full Text] [Related]
4. Anaplastic Lymphoma Kinase positive large B cell lymphoma of ileocaecal mesentery: A case report.
Subramaniam A; Gnanasekaran D; Suruliraj S; Chinnusamy P
Indian J Pathol Microbiol; 2020; 63(4):615-617. PubMed ID: 33154317
[TBL] [Abstract][Full Text] [Related]
5. ALK-positive histiocytosis with
Gupta GK; Xi L; Pack SD; Jones JB; Pittaluga S; Raffeld M; Jaffe ES
Haematologica; 2019 Nov; 104(11):e534-e536. PubMed ID: 31371408
[No Abstract] [Full Text] [Related]
6. GCC2-ALK as a targetable fusion in lung adenocarcinoma and its enduring clinical responses to ALK inhibitors.
Jiang J; Wu X; Tong X; Wei W; Chen A; Wang X; Shao YW; Huang J
Lung Cancer; 2018 Jan; 115():5-11. PubMed ID: 29290262
[TBL] [Abstract][Full Text] [Related]
7. Primary Cutaneous Anaplastic Lymphoma Kinase-Positive Large B-Cell Lymphoma.
Kempf W; Torricelli R; Zettl A; Zimmermann AK; Berisha A; Ghielmini M
Am J Dermatopathol; 2019 Aug; 41(8):602-605. PubMed ID: 31335416
[TBL] [Abstract][Full Text] [Related]
8. Arsenic trioxide inhibits anaplastic lymphoma kinase (ALK)-positive diffuse large B-cell lymphoma through targeting ALK-fusion oncoprotein.
Yue LM; Chau D; Kwong YL; Tse E
Br J Haematol; 2021 Sep; 194(6):1085-1090. PubMed ID: 34121173
[No Abstract] [Full Text] [Related]
9. RNA-based analysis of ALK fusions in non-small cell lung cancer cases showing IHC/FISH discordance.
Vollbrecht C; Lenze D; Hummel M; Lehmann A; Moebs M; Frost N; Jurmeister P; Schweizer L; Kellner U; Dietel M; von Laffert M
BMC Cancer; 2018 Nov; 18(1):1158. PubMed ID: 30466405
[TBL] [Abstract][Full Text] [Related]
10. Inflammatory Myofibroblastic Tumor Driven by Novel
Rao N; Iwenofu H; Tang B; Woyach J; Liebner DA
J Natl Compr Canc Netw; 2018 Feb; 16(2):115-121. PubMed ID: 29439172
[TBL] [Abstract][Full Text] [Related]
11. Hyperactivated STAT3 in ALK-positive diffuse large B-cell lymphoma with clathrin-ALK fusion.
Momose S; Tamaru J; Kishi H; Mikata I; Mori M; Toyozumi Y; Itoyama S
Hum Pathol; 2009 Jan; 40(1):75-82. PubMed ID: 18755494
[TBL] [Abstract][Full Text] [Related]
12. MPRIP-ALK, a Novel ALK Rearrangement That Responds to ALK Inhibition in NSCLC.
Fang W; Gan J; Hong S; Lu F; Zhang L
J Thorac Oncol; 2019 Jul; 14(7):e148-e151. PubMed ID: 31235041
[No Abstract] [Full Text] [Related]
13. Pregnancy-associated Inflammatory Myofibroblastic Tumors of the Uterus Are Clinically Distinct and Highly Enriched for TIMP3-ALK and THBS1-ALK Fusions.
Devereaux KA; Fitzpatrick MB; Hartinger S; Jones C; Kunder CA; Longacre TA
Am J Surg Pathol; 2020 Jul; 44(7):970-981. PubMed ID: 32271187
[TBL] [Abstract][Full Text] [Related]
14. Anaplastic lymphoma kinase-negative uterine inflammatory myofibroblastic tumor containing the ETV6-NTRK3 fusion gene: a case report.
Takahashi A; Kurosawa M; Uemura M; Kitazawa J; Hayashi Y
J Int Med Res; 2018 Aug; 46(8):3498-3503. PubMed ID: 29900760
[TBL] [Abstract][Full Text] [Related]
15. ALK-positive diffuse large B-cell lymphoma: two more cases and a brief literature review.
Rudzki Z; Rucińska M; Jurczak W; Skotnicki AB; Maramorosz-Kurianowicz M; Mruk A; Piróg K; Utych G; Bodzioch P; Srebro-Stariczyk M; Włodarska I; Stachura J
Pol J Pathol; 2005; 56(1):37-45. PubMed ID: 15921012
[TBL] [Abstract][Full Text] [Related]
16. Expression of C-terminal ALK, RET, or ROS1 in lung cancer cells with or without fusion.
Furugaki K; Mochizuki M; Kohno M; Shu S; Harada N; Yoshimura Y
BMC Cancer; 2019 Apr; 19(1):301. PubMed ID: 30943926
[TBL] [Abstract][Full Text] [Related]
17. Responses to crizotinib in patients with ALK-positive lung adenocarcinoma who tested immunohistochemistry (IHC)-positive and fluorescence in situ hybridization (FISH)-negative.
Ma D; Wang Z; Yang L; Mu X; Wang Y; Zhao X; Li J; Lin D
Oncotarget; 2016 Sep; 7(39):64410-64420. PubMed ID: 27418132
[TBL] [Abstract][Full Text] [Related]
18. Comparison of ALK detection by FISH, IHC and NGS to predict benefit from crizotinib in advanced non-small-cell lung cancer.
Lin C; Shi X; Yang S; Zhao J; He Q; Jin Y; Yu X
Lung Cancer; 2019 May; 131():62-68. PubMed ID: 31027700
[TBL] [Abstract][Full Text] [Related]
19. Use of ALK Immunohistochemistry for Optimal Therapeutic Strategy of Pulmonary Large-cell Neuroendocrine Carcinoma and Identification of a Novel
Shimizu N; Akashi Y; Fujii T; Shiono H; Yane K; Kitahara T; Ohta Y; Kakudo K; Wakasa T
Anticancer Res; 2019 Jan; 39(1):413-420. PubMed ID: 30591488
[TBL] [Abstract][Full Text] [Related]
20. 5'/ 3' imbalance strategy to detect ALK fusion genes in circulating tumor RNA from patients with non-small cell lung cancer.
Tong Y; Zhao Z; Liu B; Bao A; Zheng H; Gu J; McGrath M; Xia Y; Tan B; Song C; Li Y
J Exp Clin Cancer Res; 2018 Mar; 37(1):68. PubMed ID: 29587818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
